Qualys Analysts Cut Their Forecasts After Q2 Results

Qualys, Inc. QLYS reported worse-than-expected second-quarter sales results and issued FY24 revenue guidance below estimates on Tuesday.

Qualys reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.32. The company reported quarterly sales of $148.700 which missed the analyst consensus estimate of $148.699 million.

“We delivered a strong quarter of rapid innovation on the Qualys Enterprise TruRisk Platform, reflecting our ongoing commitment to extend our technology leadership and customer success,” said Sumedh Thakar, president and CEO of Qualys. “Our comprehensive multi-sensor architecture and rapid innovation engine underscore our growing thought leadership and the value proposition we deliver to customers seeking to transform, consolidate, and fortify their security posture. We believe Qualys has created strong competitive differentiation and is strategically well positioned as the foundational risk management platform for the future with multiple avenues to drive sustainable long-term growth.”

Qualys said it sees FY24 adjusted earnings of $5.46 to $5.62 per share, versus market estimates of $5.26 per share. The company expects revenue of $597.6 million to $601.5 million, versus expectations of $605.639 million.

Qualys shares fell 7.1% to trade at $127.32 on Wednesday.

These analysts made changes to their price targets on Qualys following earnings announcement.

• Piper Sandler analyst Rob Owens maintained Qualys with an Underweight and lowered the price target from $116 to $115.
• Truist Securities analyst Joel Fishbein maintained the stock with a Hold and lowered the price target from $165 to $130.
• Wedbush analyst Daniel Ives maintained the stock with an Outperform and cut the price target from $190 to $160.
• UBS analyst Roger Boyd maintained Qualys with a Neutral and cut the price target from $170 to $140.

Considering buying QLYS stock? Here’s what analysts think:

Read Next:

• How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings